Monday, September 14, 2026

HomeHealth NewsFDA approves Blenrep for relapsed or refractory multiple myeloma

FDA approves Blenrep for relapsed or refractory multiple myeloma

- Advertisement -

The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Click here to view the original article.

- Advertisment -
- Advertisement -

Recently Viewed